CanSino Biologics, Inc. Class H (HK:6185) has released an update.
CanSino Biologics Inc. has announced the approval of phase I/II clinical trials in Indonesia for its Recombinant Poliomyelitis Vaccine (CS-2036), a promising non-infectious candidate based on VLP technology. The vaccine, aligning with WHO’s future polio eradication goals, could potentially be integrated into combined vaccines. Investors are cautioned to trade carefully with the company’s shares amidst these developments.
For further insights into HK:6185 stock, check out TipRanks’ Stock Analysis page.
